EYLEA4U has support for all eligible patients

EYLEA4U is committed to help ensure your eligible patients have access to EYLEA for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (MEfRVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR). Our programs include*:

EYLEA4U® logo.
Copay card program for EYLEA cost assistance.
EYLEA Copay Card Program

With the EYLEA Copay Card, patients with commercial healthcare coverage may be eligible to pay as little as a $0 copay for each EYLEA treatment.†,‡ Subject to annual assistance limit.

See the program
Eligible patients can receive EYLEA at no cost.
Patient Assistance Program

No insurance or no coverage for EYLEA? No problem. The Patient Assistance Program (PAP) from EYLEA4U can provide EYLEA free of charge to eligible patients.II

Get more information
Alternate Coverage Referral process information.
Alternate Coverage Referral

EYLEA4U can provide
information about the referral process, which connects patients in need to independent charitable foundations.§

Learn about the process
Did you know? More than 39,000 patients

received support through the EYLEA Commercial Copay Card Program in 2018.*

*EYLEA4U EBR Report 2019.

Find the right copay support for your patients

Follow this flowchart to determine how to connect your patients to the right program for help with out-of-pocket costs.

EYLEA4U® contact information

The EYLEA4U Enrollment Form is completed and Copay Card Program/Alternate Coverage Referral is selected.

EYLEA4U verifies benefits and whether patient has
an out-of-pocket cost for EYLEA.

Is patient insured by a commercial
or private insurer?

EYLEA Copay Card Program
Eligible patients who have commercial insurance, not funded through a government healthcare program, may qualify for help with their EYLEA out-of-pocket copay costs..

YES

NO

Alternate Coverage Referral
For patients who need help with their out-of-pocket costs, EYLEA4U can assist with the referral process to an independent charitable foundation for approved indications.*

EYLEA® (aflibercept) Injection out-of-pocket costs flowchart.
  • *Regeneron does not influence or control the operations of independent charitable foundations and cannot guarantee assistance will be provided.

EYLEA4U Enrollment Form

Complete the EYLEA4U Enrollment Form to begin the process of helping your patients determine copay assistance eligibility.

{{f.FileSize}}mb
{{DownloadFormModel.OutputFileName}}.zip  {{DownloadFormModel.DownloadSize}} MB
In My Eyes by Regeneron logo.

Experience what certain retinal diseases can be like in virtual reality

Retinal disease virtual and augmented reality app.
  • Available on the App Store.
  • Android app on Google play.

A powerful tool to use with your patients and caregivers, this unique app lets the user experience symptoms of degenerative eye disease, such as diabetic retinal changes, firsthand in a 360° view. In My Eyes uses virtual reality and augmented reality to show the impact of vision impairment on everyday situations.

Retinal disease virtual and augmented reality app.
  • Available on the App Store
  • Android app on Google play
Product support for EYLEA® (aflibercept) Injection.
Product Support

Find complete product support—
guiding you through
orders, returns, and more.

Learn how it works
Support for the reimbursement process.
Reimbursement Support

Get information about navigating the
reimbursement process. Find enrollment forms, learn about PA assistance, and more.

See the details
EYLEA news, events, and more.
Resources

Get the information you
and your patients need
about EYLEA.

See resources
See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

Reference
  1. Data on file. Regeneron Pharmaceuticals, Inc.